# US 2022/0389112 A1 · Treatment of multiple myeloma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0389112 A1
- Document ID: US20220389112A1
- Status: Published application
- Kind: A1
- Application number: 17/774,276
- Filed: 2020-11-06
- Published: 2022-12-08
- Earliest claimed: 2019-11-06
- Assignees: National University of Ireland, Galway
- Applicants: National University of Ireland, Galway
- Inventors: Michael O'DWYER; John DALY; Sarkar SUBHASHIS
- Web page: https://patentgrep.com/patent/US20220389112A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 31/351: not condensed with another ring
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/4222: {CD38 not IgG}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12N 9/24: acting on glycosyl compounds (3.2)
- C12Y 302/02005: NAD+ nucleosidase (3.2.2.5)
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided is an effective amount of a desialylation agent and an effective amount of an anti CD38 antibody for use in the treatment of multiple myeloma. This results in potentiated primary NK cell activity against the multiple myeloma cell. Also envisaged is a method of treating multiple myeloma in a subject in need thereof.

## Claims

### Claim 1

An effective amount of a desialylation agent and an effective amount of a CD38 targeting agent, for use in the treatment of a CD38 positive disease.

### Claim 2 (depends on 1)

The desialylation agent and CD38 targeting agent for use of claim 1, in which the disease is selected from the group comprising a haematological malignancy, including large B cell lymphoma, T cell acute lymphoblastic leukaemia (T-ALL), acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL) and multiple myeloma.

### Claim 3 (depends on 2)

The desialylation agent and CD38 targeting agent for use of claim 2, in which the disease is multiple myeloma.

### Claim 4

The desialylation agent and CD38 targeting agent for use any one of the preceding claims, further comprising a modified NK cell.

### Claim 5

The desialylation agent and CD38 targeting agent for use of any one of the preceding claims, further comprising an effective amount of an agent that increases the expression of CD38 on the surface of a cell.

### Claim 6

The desialylation agent and CD38 targeting agent for use of any one of the preceding claims, wherein the desialylation agent is selected from the group comprising a sialidase enzyme and sialytransferase inhibitor (SIA).

### Claim 7

The desialylation agent and CD38 targeting agent for use of any one of the preceding claims, in which the CD38 targeting agent is selected from the group comprising a peptide, a small molecule, a peptide mimic, an antagonist, an antibody and an immune cell.

### Claim 8 (depends on 7)

The desialylation agent and CD targeting agent for use of claim 7, wherein the agent is a chimeric antigen receptor for CD38.

### Claim 9 (depends on 7)

The desialylation agent and CD38 targeting agent for use of claim 7, wherein the antibody is a monoclonal antibody.

### Claim 10 (depends on 7)

The desialylation agent and CD38 targeting agent for use of claim 7, wherein the CD38 targeting agent is an immune cell that expresses an antigen receptor targeting CD38.

### Claim 11 (depends on 10)

The desialylation agent and CD38 targeting agent for use of claim 10, in which the immune cell is an NK cell or a T cell.

### Claim 12

The desialylation agent and CD38 targeting agent for use of any one of the preceding claims, wherein the desialylation agent and the CD38 binding agent are in the form of a conjugate.

### Claim 13 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12)

The desialylation agent and CD38 targeting agent for use of any one of claims 4 to 12, wherein the modified NK cell is an NK cell that does not express CD38 or has reduced expression of CD38 compared to an unmodified cell.

### Claim 14

An effective amount of a desialylation agent, an effective amount of an agent that increases the expression of CD38 on the surface of a cell, and an effective amount of a CD38 targeting agent, for use in the treatment of a CD38 positive disease.

### Claim 15

An effective amount of a desialylation agent, an effective amount of a modified NK cell and an effective amount of a CD38 targeting agent for use in the treatment of a CD38 positive disease.

### Claim 16

An effective amount of a desialylation agent, an effective amount of a modified NK cell, an effective amount of an agent that increases the expression of CD38 on the surface of a multiple myeloma cell and an effective amount of a CD38 binding agent, for use in the treatment of a CD38 positive disease.

### Claim 17

A conjugate comprising a desialylation agent and a CD38 targeting agent.

### Claim 18 (depends on 17)

The conjugate of claim 17, in which the CD38 targeting agent is an anti CD38 antibody.

### Claim 19 (depends on 17, 18)

A composition comprising the conjugate of claim 17 or 18.

### Claim 20 (depends on 19)

The composition of claim 19, further comprising an effective amount of an agent that increases the expression of CD38 on the surface of a cell.

### Claim 21 (depends on 19, 20)

The composition of claim 19 or 20, comprising an effective amount of a modified NK cell that does not express CD38 or has reduced expression of CD38 compared to an unmodified cell.

### Claim 22

A method for the treatment of a CD38 positive disease in a subject, said method comprising administration of a desialylation agent and a CD38 targeting agent, to said subject.

### Claim 23 (depends on 22)

The method of claim 22, in which the disease is multiple myeloma.

### Claim 24 (depends on 22, 23)

The method of claim 22 or 23, comprising administration of a modified NK cell.

### Claim 25 (depends on 22, 23, 24)

The method of any one of claims 22 to 24, comprising administration of an agent that increases the expression of CD38 on the surface of a cell.

### Claim 26 (depends on 22, 23, 24, 25)

The method of any one of claims 22 to 25, wherein the desialylation agent is selected from the group comprising a sialidase enzyme and sialytransferase inhibitor (SIA).

### Claim 27 (depends on 22, 23, 24, 25, 26)

The method of any one of claims 22 to 26, wherein the CD38 targeting agent is selected from the group comprising a peptide, a small molecule, a peptide mimic, an antagonist, an antibody and an immune cell.
